-
公开(公告)号：US20160289171A1
公开(公告)日：2016-10-06
申请号：US15088211
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: C07C229/42 , A61K31/196 , C07D239/47 , A61K31/505 , C07C255/58 , A61K31/277 , C07C275/40 , A61K31/17 , C07D295/155 , A61K31/5375 , C07D277/64 , A61K31/428 , C07D335/02 , A61K31/382 , C07D409/12 , A61K31/506 , C07D309/04 , A61K31/351 , C07D405/12 , C07D211/14 , A61K31/445 , C07D401/12 , C07D413/12 , A61K31/5377 , C07D405/14 , C07D417/12 , C07D487/04 , A61K31/519 , A61K31/501 , C07D471/04 , A61K31/437 , C07D205/04 , A61K31/397 , A61K31/538 , C07D265/36 , A61K39/395
CPC classification number: C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
Abstract translation: 公开了调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病如癌症，病毒感染和/或炎症性疾病的方法，其利用 发明。
-
公开(公告)号：US10167254B2
公开(公告)日：2019-01-01
申请号：US15584818
申请日：2017-05-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: A61K31/17 , C07C275/40 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C229/42 , C07C255/58 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D309/14 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56 , C07C233/81 , C07C275/42 , C07D207/12 , C07D239/34 , C07D317/46 , C07D413/14 , C07D471/08 , C07C275/30 , A61K45/06
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US11066392B2
公开(公告)日：2021-07-20
申请号：US16612076
申请日：2018-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Liping Zhang , Audris Huang , Weifang Shan , David K. Williams , Xiao Zhu , Weiwei Guo
IPC: A61P35/00 , A61K31/444 , A61K31/4709 , A61K31/4375 , A61K31/497 , A61K31/506 , C07D401/12 , C07D403/12 , C07D471/04 , C07D213/85
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US20180072660A1
公开(公告)日：2018-03-15
申请号：US15564153
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Weiwei Guo , Audris Huang , Jay A. Markwalder , Weifang Shan , David K. Williams , Susheel Jethanand Nara , Saumya Roy
IPC: C07C275/40 , C07C275/30
Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US09790169B2
公开(公告)日：2017-10-17
申请号：US15088211
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: C07C229/42 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C255/58 , C07C275/40 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D309/14 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56
CPC classification number: C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
Patent Agency Ranking
公开(公告)号：US20170231999A1
公开(公告)日：2017-08-17
申请号：US15584818
申请日：2017-05-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Emily Charlotte Cherney , Weiwei Guo , Audris Huang , Jay A. Markwalder , Steven P. Seitz , Weifang Shan , David K. Williams , Natesan Murugesan , Susheel Jethanand Nara , Saumya Roy , Soodamani Thangavel , Ramesh Kumar Sistla , Srinivas Cheruku , Srinivasan Thangathirupathy , Yadagiri Kanyaboina , Nagalakshmi Pulicharla
IPC: A61K31/538 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K39/395 , A61K45/06
CPC classification number: C07C275/40 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07C229/42 , C07C233/81 , C07C235/38 , C07C235/56 , C07C255/57 , C07C255/58 , C07C275/30 , C07C275/42 , C07D205/04 , C07D207/08 , C07D207/12 , C07D211/08 , C07D211/14 , C07D239/34 , C07D239/47 , C07D265/30 , C07D265/36 , C07D277/64 , C07D295/155 , C07D307/22 , C07D309/04 , C07D309/14 , C07D317/46 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08
Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US20160115126A1
公开(公告)日：2016-04-28
申请号：US14921347
申请日：2015-10-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Qingjie Liu , Scott Hunter Watterson , Douglas G. Batt , Saleem Ahmad , Myra Beaudoin Bertrand , Hua Gong , Weiwei Guo , John E. Macor , Khehyong Ngu , Andrew J. Tebben , Joseph A. Tino
IPC: C07D209/08 , C07D403/10 , C07D403/12 , C07D403/04 , C07D487/10 , C07D487/04 , C07D413/04 , C07D471/04 , C07D401/06 , C07D417/04 , C07D401/04 , C07D401/12
CPC classification number: C07D401/10 , C07D209/08 , C07D209/18 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D413/04 , C07D417/04 , C07D471/04 , C07D487/04 , C07D487/10
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Abstract translation: 公开了式（I）的化合物或其盐，其中：X是CR 4或N; R1，R2，R3，R4和A在本文中定义。 还公开了使用这种化合物作为Bruton酪氨酸激酶（Btk）的抑制剂的方法和包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫性疾病和血管疾病）中的疾病或病症的进展。
-
公开(公告)号：US09221819B2
公开(公告)日：2015-12-29
申请号：US14503456
申请日：2014-10-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： T. G. Murali Dhar , John V. Duncia , Daniel S. Gardner , Weiwei Guo , John Hynes
IPC: C07D471/10 , A61K31/4427 , C07D401/12 , C07D405/12 , C07D413/12 , C07D471/04
CPC classification number: C07D471/10 , A61K31/4427 , C07D401/12 , C07D405/12 , C07D413/12 , C07D471/04
Abstract: The present application describes modulators of chemokine receptor activity of formula I or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
Abstract translation: 本申请描述了式I的趋化因子受体活性的调节剂或其立体异构体或其药学上可接受的盐。 此外，公开了使用式（I）的调节剂治疗和预防炎性疾病如哮喘和过敏性疾病以及类风湿性关节炎和移植排斥反应的自身免疫病态的方法。
-
公开(公告)号：US10399933B2
公开(公告)日：2019-09-03
申请号：US15564153
申请日：2016-04-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James Aaron Balog , Weiwei Guo , Audris Huang , Jay A. Markwalder , Weifang Shan , David K. Williams , Susheel Jethanand Nara , Saumya Roy
IPC: C07D309/14 , C07C275/40 , C07D211/10 , A61K31/17 , A61K31/196 , A61K31/277 , A61K31/351 , A61K31/382 , A61K31/397 , A61K31/428 , A61K31/437 , A61K31/445 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/5375 , A61K31/5377 , A61K31/538 , A61K39/395 , C07C229/42 , C07C255/58 , C07D205/04 , C07D211/14 , C07D239/47 , C07D265/36 , C07D277/64 , C07D295/155 , C07D309/04 , C07D335/02 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D407/12 , C07D487/08 , C07D265/30 , C07D207/08 , C07D211/08 , C07D307/22 , C07C255/57 , C07C235/38 , C07C235/56 , C07C233/81 , C07C275/42 , C07D207/12 , C07D239/34 , C07D317/46 , C07D413/14 , C07D471/08 , C07C275/30 , A61K45/06
Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
-
公开(公告)号：US20170260160A1
公开(公告)日：2017-09-14
申请号：US15608340
申请日：2017-05-30
Applicant: Bristol-Myers Squibb Company
Inventor： Qingjie Liu , Scott Hunter Watterson , Douglas G. Batt , Saleem Ahmad , Myra Beaudoin Bertrand , Hua Gong , Weiwei Guo , John E. Macor , Khehyong Ngu , Andrew J. Tebben , Joseph A. Tino
IPC: C07D401/10 , C07D209/18 , C07D401/04 , C07D487/04 , C07D401/12 , C07D471/04 , C07D487/10 , C07D209/08 , C07D401/06
CPC classification number: C07D401/10 , C07D209/08 , C07D209/18 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D413/04 , C07D417/04 , C07D471/04 , C07D487/04 , C07D487/10
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.051 seconds)
